Neurology

The FDA recently accepted the sNDA for brexpiprazole in combination with sertraline and set a PDUFA target action date for February 2025.

The AHEAD study program will use plasma biomarker screening, novel PET agents, and other unique approaches to assessing lecanemab effect at the earliest stage of disease.

Following a decrease, suicide rates among US preteens increased annually by 8.2% from 2008 to 2022, according to a recent cross-sectional study.

Your daily dose of the clinical news you may have missed.

Findings from a new study suggest high-intensity interval training may be more effective in improving individuals’ cardiorespiratory fitness poststroke than moderate-intensity continuous training.

New study findings suggest that in older adults stable HbA1c within individualized target ranges over time may help reduce risk of Alzheimer disease and other dementias.

The lecanemab Clarity AD open label extension study returned no new safety signals and data reflect the therapy's disease modifying effects on key biomarkers.

Three out of 5 US youths who died by suicide between 2010 and 2021 did not have a documented preceding mental health diagnosis, researchers reported.

A blood test had a diagnostic accuracy of 91% compared with 61% accuracy by primary care clinicians and 73% by dementia specialists, according to new research.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

Your daily dose of the clinical news you may have missed.

Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.

From top barriers in seeking treatment to how well mental health issues are identified and treated, find out what US adults really think about the mental health care system.

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

Your daily dose of the clinical news you may have missed.